MedTrace Logo

RET Inhibitor for Neoadjuvant Therapy in Locally Advanced RET-altered Thyroid Cancer

NCT06530316 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 48

Last updated 2024-08-02

No results posted yet for this study

Summary

This study is a multicenter observational study. Patients receive neoadjuvant therapy with RET inhibitors in the real world, and those who can undergo surgery after neoadjuvant therapy receive surgical treatment. The aim of the study is to determine the efficacy and safety of RET inhibitors for neoadjuvant therapy in locally advanced RET-altered thyroid cancer.

Conditions

Interventions

DRUG

RET Inhibitor

RET inhibitors for neoadjuvant treatment

PROCEDURE

Surgery

Operable patients receive surgery after neoadjuvant therapy

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Eligibility

Min Age
14 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-18
Primary Completion
2026-12-31
Completion
2029-12-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06530316 on ClinicalTrials.gov